Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260517 | 0.86 | KDM4E (0.52) | GABRA1GABRB2TAS1R3TAS1R1GAA | |
| SCHEMBL200964 | 0.84 | GABRA1 (0.54) | NPC1RAB9AGABRA1GABRB2ADORA3 | |
| SCHEMBL2262131 | 0.81 | RAB9A (0.60) | NPC1RAB9AGAAKMT2AHPGD | |
| SCHEMBL2261168 | 0.81 | NPC1 (0.62) | NPC1RAB9AKMT2AHPGDERN1 | |
| SCHEMBL2260303 | 0.81 | NPC1 (0.65) | NPC1RAB9AADORA3ADORA1KMT2A | |
| SCHEMBL2261442 | 0.80 | MCHR1 (0.59) | NPC1RAB9AGABRA1GABRB2ADORA3 | |
| SCHEMBL2260433 | 0.80 | NPC1 (0.67) | NPC1RAB9AKMT2AHPGDERN1 | |
| SCHEMBL2262389 | 0.80 | AKR1C4 (0.48) | NPC1RAB9AGABRA1GABRB2ADORA3 | |
| SCHEMBL11142926 | 0.80 | TAS1R3 (0.67) | NPC1RAB9ATAS1R3TAS1R1KMT2A | |
| SCHEMBL2261354 | 0.79 | NPC1 (0.66) | NPC1RAB9AKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989454-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989454-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989454-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-10-08 | — | — | US | disclosed |
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-10-08 | — | — | US | disclosed |
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | NPC1 689/4885RAB9A 3108/4885GABRA1 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.